Graph Therapeutics
Agent41Agent Readiness: 41/100. Above median. Measured by StartupHub.ai. Median 41.Developing precision medicines for inflammatory and immune-mediated diseases using AI and patient sample analysis.
About
Graph Therapeutics is a next-generation techbio company focused on developing precision medicines for inflammatory and immune-mediated diseases. They leverage a proprietary 'lab-in-the-loop' AI platform that combines perturbation modeling of live patient samples, functional and multi-omics profiling, and advanced machine learning to understand immune dysfunction at scale. By analyzing real patient tissue, Graph identifies disease mechanisms, novel therapeutic targets, and biomarkers to create differentiated therapies.
Listed competitors
Key facts
At-a-glance profile data
- Website
- graphtx.com
- Headquarters
- Austria
- Founded
- 2021
- Total funding
- $5M (Funding Round)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 22 Jun 2026 | Funding Round | $5M | Daphni |
Tech stack
Detected on graphtx.com, last scanned 7 Sept 2026. Run your own scan
- CMS / Builders
- Framer
- Email provider
- Google Workspace
Frequently asked
What does Graph Therapeutics do?
The company has a validated platform and is advancing an internal pipeline of therapeutics, while also exploring strategic partnerships and out-licensing opportunities.
How much funding has Graph Therapeutics raised?
Graph Therapeutics has raised a total of $5M in funding. The most recent round on record is Funding Round.